In the following video, David Williamson highlights the game-changing trial results that sent shares of Vertex Pharmaceuticals soaring 55% in a single day. Known for its blockbuster hepatitis C franchise Incivek, Vertex may have another megahit on its hands as it expands the use of cystic fibrosis treatment Kalydeco. For a closer look at Vertex and what investors should make of the market's reaction, watch the video and Fool on.
Vertex is one of the many dynamic recommendations made to Rule Breakers subscribers over the years, but this is now a great time to discover the next rule-breaking multibagger that the newsletter has unearthed. It's a free report. Want it? Get it.
At the time thisarticle was published David Williamsonholds no position in any company mentioned.Click hereto see his holdings and a short bio.Motley Fool newsletter serviceshave recommended buying shares of Gilead Sciences and Vertex Pharmaceuticals. The Motley Fool has adisclosure policy. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. Try any of our Foolish newsletter servicesfree for 30 days.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.